S&P Futures
4,160.00+4.50(+0.11%)Dow Futures
33,975.00+17.00(+0.05%)Nasdaq Futures
13,924.75+27.50(+0.20%)
Aptinyx Inc. (APTX)
Chart Events
Performance Outlook
| Previous Close | 2.6800 |
| Open | 2.6800 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 1000 |
| Day's Range | 2.6200 - 2.7600 |
| 52 Week Range | 2.0400 - 6.4700 |
| Volume | 423,559 |
| Avg. Volume | 568,573 |
| Market Cap | 182.158M |
| Beta (5Y Monthly) | 1.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0240 |
| Earnings Date | May 12, 2021 - May 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.57 |
- Business Wire
Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022.
- Simply Wall St.
Aptinyx (NASDAQ:APTX) Shareholders Have Enjoyed A 32% Share Price Gain
Aptinyx Inc. ( NASDAQ:APTX ) shareholders might be concerned after seeing the share price drop 22% in the last month...
- Motley Fool
Aptinyx Inc. (APTX) Q4 2020 Earnings Call Transcript
At this time, I would like to turn the call over to Nick Smith, vice president of corporate development and investor relations of Aptinyx. On today's call, Norbert Riedel, our chief executive officer, will discuss our business and clinical development progress, and Ashish Khanna, our chief financial officer, and the chief business officer will review our financial results.
